Literature DB >> 12915442

LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.

Emmanuelle Bitoun1, Alessia Micheloni, Laurence Lamant, Chrystelle Bonnart, Alessandro Tartaglia-Polcini, Christian Cobbold, Talal Al Saati, Feliciana Mariotti, Juliette Mazereeuw-Hautier, Franck Boralevi, Daniel Hohl, John Harper, Christine Bodemer, Marina D'Alessio, Alain Hovnanian.   

Abstract

SPINK5, encoding the putative multi-domain serine protease inhibitor LEKTI, was recently identified as the defective gene in the severe autosomal recessive ichthyosiform skin condition, Netherton syndrome (NS). Using monoclonal and polyclonal antibodies, we show that LEKTI is a marker of epithelial differentiation, strongly expressed in the granular and uppermost spinous layers of the epidermis, and in differentiated layers of stratified epithelia. LEKTI expression was also demonstrated in normal differentiated human primary keratinocytes (HK) through detection of a 145 kDa full-length protein and a shorter isoform of 125 kDa. Both proteins are N-glycosylated and rapidly processed in a post-endoplasmic reticulum compartment into at least three C-terminal fragments of 42, 65 and 68 kDa, also identified in conditioned media. Processing of the 145 and 125 kDa precursors was prevented in HK by treatment with a furin inhibitor. In addition, in vitro cleavage of the recombinant 145 kDa precursor by furin generated C-terminal fragments of 65 and 68 kDa, further supporting the involvement of furin in LEKTI processing. In contrast, LEKTI precursors and proteolytic fragments were not detected in differentiated HK from NS patients. Defective expression of LEKTI in skin sections was a constant feature in NS patients, whilst an extended reactivity pattern was observed in samples from other keratinizing disorders, demonstrating that loss of LEKTI expression in the epidermis is a diagnostic feature of NS. The identification of novel processed forms of LEKTI provides the basis for future functional and structural studies of fragments with physiological relevance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915442     DOI: 10.1093/hmg/ddg247

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  26 in total

1.  Overexpression of YAP1 induces immortalization of normal human keratinocytes by blocking clonal evolution.

Authors:  Irene D'Addario; Claudia Abbruzzese; Marco Lo Iacono; Massimo Teson; Osvaldo Golisano; Virginia Barone
Journal:  Histochem Cell Biol       Date:  2010-07-31       Impact factor: 4.304

2.  Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.

Authors:  Wei-Li Di; Fernado Larcher; Ekaterina Semenova; Gill E Talbot; John I Harper; Marcela Del Rio; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

3.  LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Authors:  Celine Deraison; Chrystelle Bonnart; Frederic Lopez; Celine Besson; Ross Robinson; Arumugam Jayakumar; Fredrik Wagberg; Maria Brattsand; Jean Pierre Hachem; Goran Leonardsson; Alain Hovnanian
Journal:  Mol Biol Cell       Date:  2007-06-27       Impact factor: 4.138

4.  Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.

Authors:  Mohamed O Abdalla; Prasanthi Karna; Hari Krishna Sajja; Hui Mao; Clayton Yates; Timothy Turner; Ritu Aneja
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

Review 5.  Prenatal diagnosis of Comel-Netherton syndrome with PGD, case report and review article.

Authors:  Banu Bingol; Seval Tasdemir; Ziya Gunenc; Faruk Abike; Semra Esenkaya; Safak Tavukcuoglu; Hakan Berkil
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

Review 6.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 7.  Epidermal barriers.

Authors:  Ken Natsuga
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 8.  Netherton Syndrome: A Genotype-Phenotype Review.

Authors:  Constantina A Sarri; Angeliki Roussaki-Schulze; Yiannis Vasilopoulos; Efterpi Zafiriou; Aikaterini Patsatsi; Costas Stamatis; Polyxeni Gidarokosta; Dimitrios Sotiriadis; Theologia Sarafidou; Zissis Mamuris
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

9.  Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.

Authors:  Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.

Authors:  Anaïs Briot; Céline Deraison; Matthieu Lacroix; Chrystelle Bonnart; Aurélie Robin; Céline Besson; Pierre Dubus; Alain Hovnanian
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.